ClinicalTrials.gg
CompletedNCT01192867Updated Jun 26, 2017

A Study of RO4917838 in Participants With Persistent, Predominant Negative Symptoms of Schizophrenia (NN25310)

A Phase 3 interventional study of Placebo and RO4917838 in Schizophrenia, sponsored by Hoffmann-La Roche. Completed at 122 sites in 14 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-06-26.

Sponsored by Hoffmann-La Roche · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
629
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 19 studies in Schizophrenia by Hoffmann-La Roche — none open to participants now, none under way, none of them phase 3. Schizophrenia · Hoffmann-La Roche.

Enrollment
Largest of 16
629 · median 294
Started
2010
with 5 others
Phase 3
6 of 19
none open now
Registered
3rd of 19
by date

Among the 19 studies in Schizophrenia by Hoffmann-La Roche, this one has the largest enrollment of the 16 interventional ones that give a count, is one of 6 that started in 2010, is one of 6 in phase 3, and was the 3rd registered.

Schizophrenia

3,571 studies on the registry are indexed under Schizophrenia; 494 are open to participants now.

Browse Schizophrenia studies →

Open to participants now

None of the 19 studies in Schizophrenia by Hoffmann-La Roche is open now. The open studies under Schizophrenia, anywhere →

Who these studies take

Of the 333 Schizophrenia studies recruiting now, 63 (19%) set no upper age limit and 258 (77%) stop at 75 or younger; 42 take children under 18; 83 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 19 studies in Schizophrenia by Hoffmann-La Roche as a file.
02

Study summary

This multi-center, randomized, double-blind, parallel-group, placebo-controlled study will evaluate the efficacy and safety of RO4917838 in participants with persistent, predominant negative symptoms of schizophrenia. Participants, on stable treatment with antipsychotics, will be randomized to receive daily oral doses of RO4917838 or matching placebo for 56 weeks (treatment period 1 of 24 weeks and treatment period 2 of 32 weeks), followed by an optional treatment extension for up to 3 years. After 52 weeks, participants who were originally randomized to an active treatment will be randomly assigned to receive either placebo or continue on the originally assigned study treatment for 4 weeks washout period (Week 52 to Week 56) for the assessment of potential withdrawal effects in a blinded manner using participants staying on active treatment as a control. Participants initially randomized to placebo will remain on placebo. After 56 weeks, participants who were switched to placebo in the washout period will return to their blinded, active treatment arm.

03

Conditions studied

  • Schizophrenia

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of schizophrenia of paranoid, disorganized, residual, undifferentiated or catatonic subtype
  • Predominant negative symptoms
  • With the exception of clozapine, participants are on any of the available marketed atypical or typical antipsychotics (treatment with a maximum of two antipsychotics)

Exclusion criteria

Exclusion Criteria:

  • Evidence that participant has , uncontrolled and unstable disorder (e.g. cardiovascular, renal, hepatic disorder)
  • (BMI) of less than (\<) 17 or greater than (>) 40 kilograms per meter square (kg/m\^2)
  • Depressive symptoms, defined as a score of 9 or greater on the Calgary Depression Rating Scale for Schizophrenia (CDSS)
  • A severity score of 3 or greater on the Parkinsonism item of the Exrapyramidal Symptoms Rating Scale-Abbreviated (ESRS-A) (Clinical Global Impression, Parkinsonism)
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
629 participants (actual)

Study arms

  • Experimental
    RO4917838 20 milligrams (mg)

    Participants, on stable antipsychotics, will receive RO4917838 orally at 20 mg once daily (QD) up to 56 weeks followed by an optional treatment extension for up to 3 years.

    Drug: RO4917838 · Drug: Antipshychotics (Standard of Care)

  • Experimental
    RO4917838 10 mg

    Participants, on stable antipsychotics, will receive RO4917838 orally at 10 mg QD up to 56 weeks followed by an optional treatment extension for up to 3 years.

    Drug: RO4917838 · Drug: Antipshychotics (Standard of Care)

  • Placebo comparator
    Placebo

    Participants, on stable antipsychotics, will receive RO4917838 matching placebo orally QD up to 56 weeks.

    Drug: Placebo · Drug: Antipshychotics (Standard of Care)

Interventions

  • DrugPlacebo

    Placebo will be administered orally QD for 56 weeks

  • RO4917838 will be administered orally at 20 or 10 mg QD for 56 weeks.

  • DrugAntipshychotics (Standard of Care)

    Participants will continue to receive their stable antipshychotic as standard of care based on their prescription up to Week 56.

06

What researchers measure

Primary outcomes

  1. Change From Baseline in the Positive and Negative Symptoms Scales (PANSS) Negative Symptoms Factor Score at Week 24 (All-Participant Population)

    Time frame: Baseline, Week 24

  2. Percentage of Participants With Adverse Events (All-Participant Population)

    Time frame: Week 24

Secondary outcomes

  1. Change From Baseline in the PANSS Negative Symptoms Factor Score at Week 24 (Complement Factor H Related Protein 1 High [CFHR1-High] Subgroup Population)

    Time frame: Baseline, Week 24

  2. Change From Baseline in the Personal and Social Performance (PSP) Total Score at Week 24 (All-Participant Population)

    Time frame: Baseline, Week 24

  3. Change From Baseline in the PSP Total Score at Week 24 (CFHR1-High Subgroup Population)

    Time frame: Baseline, Week 24

  4. Change From Baseline in the PANSS Total Score at Week 24 (All-Participant Population)

    Time frame: Baseline, Week 24

  5. Change From Baseline in the PANSS Total Score at Week 24 (CFHR1-High Subgroup Population)

    Time frame: Baseline, Week 24

  6. Change From Baseline in the PANSS Factor Score at Week 24 (All-Participant Population)

    Time frame: Baseline, Week 24

  7. Change From Baseline in the PANSS Factor Score at Week 24 (CFHR1-High Subgroup Population)

    Time frame: Baseline, Week 24

  8. Change From Baseline in the PANSS Subscale Scores at Week 24 (All-Participant Population)

    Time frame: Baseline, Week 24

  9. Change From Baseline in the PANSS Subscale Scores at Week 24 (CFHR1-High Subgroup Population)

    Time frame: Baseline, Week 24

  10. Percentage of Participants Who Have at least 20 Percent (%) Improvement From Baseline in the PANSS Negative Symptom Factor Score at Week 24 (All-Participant Population)

    Time frame: Baseline, Week 24

  11. Percentage of Participants Who Have at least 20% Improvement From Baseline in the PANSS Negative Symptom Factor Score at Week 24 (CFHR1-High Subgroup Population)

    Time frame: Baseline, Week 24

  12. Percentage of Participants Who Have at least 20% Improvement From Baseline in the PANSS Negative Symptom Factor Score for Two out of Three Assessments During 24 Weeks (All-Participant Population)

    Time frame: Baseline up to Week 24

  13. Percentage of Participants Who Have at least 20% Improvement From Baseline in the PANSS Negative Symptom Factor Score for Two out of Three Assessments During 24 Weeks (CFHR1-High Subgroup Population)

    Time frame: Baseline up to Week 24

  14. Percentage of Participants With Improvement From Baseline in the Overall Clinical Status Based on Clinical Global Impression - Improvement (CGI-I) Score (All-Participant Population)

    Time frame: Baseline, Week 24

  15. Percentage of Participants With Improvement From Baseline in the Overall Clinical Status Based on CGI-I Score (CFHR1 Subgroup Population)

    Time frame: Baseline, Week 24

  16. Percentage of Participants With Improvement From Baseline in the Overall Clinical Status Based on CGI-I Score for Two out of Three Assessments During 24 Weeks (All-Participant Population)

    Time frame: Baseline up to Week 24

  17. Percentage of Participants With Improvement From Baseline in the Overall Clinical Status Based on CGI-I Score for Two out of Three Assessments During 24 Weeks (CFHR1 Subgroup Population)

    Time frame: Baseline up to Week 24

  18. Percentage of Participants With Improvement From Baseline in the Negative Symptoms Based on CGI-I Negative Symptoms Score (All-Participant Population)

    Time frame: Baseline, Week 24

  19. Percentage of Participants With Improvement From Baseline in the Negative Symptoms Based on CGI-I Negative Symptoms Score (CFHR1 Subgroup Population)

    Time frame: Baseline, Week 24

  20. Percentage of Participants With Improvement From Baseline in the Negative Symptoms Based on CGI-I Negative Symptoms Score for Two out of Three Assessments During 24 Weeks (All-Participant Population)

    Time frame: Baseline up to Week 24

  21. Percentage of Participants With Improvement From Baseline in the Negative Symptoms Based on CGI-I Negative Symptoms Score for Two out of Three Assessments During 24 Weeks (CFHR1 Subgroup Population)

    Time frame: Baseline up to Week 24

  22. Percentage of Participants Who Have at least 20% Improvement From Baseline in the PANSS Negative Symptom Factor Score at Week 24 and Improvement in the Negative Symptoms Based on CGI-I Negative Symptoms Score (All-Participant Population)

    Time frame: Baseline, Week 24

  23. Percentage of Participants Who Have at least 20% Improvement From Baseline in the PANSS Negative Symptom Factor Score at Week 24 and Improvement in the Negative Symptoms Based on CGI-I Negative Symptoms Score (CFHR1 Subgroup Population)

    Time frame: Baseline, Week 24

  24. Change From Baseline in Severity of Illness Based on Clinical Global Impression - Severity (CGI-S) Overall Score (All-Participant Population)

    Time frame: Baseline, Week 24

  25. Change From Baseline in Severity of Illness Based on CGI-S Overall Score (CFHR1 Subgroup Population)

    Time frame: Baseline, Week 24

  26. Change From Baseline in Severity of Illness Based on CGI-S Negative Symptoms Score (All-Participant Population)

    Time frame: Baseline, Week 24

  27. Change From Baseline in Severity of Illness Based on CGI-S Negative Symptoms Score (CFHR1 Subgroup Population)

    Time frame: Baseline, Week 24

07

Study locations

122 sites
  • K&S Professional Research Services LLC
    Little Rock, Arkansas 72201, United States
  • Advanced Research Center Inc.
    Anaheim, California 92805, United States
  • Comprehensive Clinical Development- Cerritos CA
    Cerritos, California 90703, United States
  • Diligent Clinical Trials Inc
    Downey, California 90241, United States
  • Care Research Center
    La Palma, California 90623, United States
  • Pasadena Research Institute
    Pasadena, California 91106, United States
  • CNRI - Los Angeles, LLC
    Pico Rivera, California 90660, United States
  • Pharmax Research Clinic Inc.
    Miami, Florida 33126, United States
  • Northwest Behavioral Research Center
    Marietta, Georgia 30060, United States
  • American Medical Research, Inc
    Oak Brook, Illinois 60523, United States
  • University of Iowa College of Medicine; Psychiatry Research
    Iowa City, Iowa 52242, United States
  • Clinical Insights, Inc.
    Glen Burnie, Maryland 21061, United States
  • St Louis Clinical Trials
    Saint Louis, Missouri 63141, United States
  • Ocean Rheumatology
    Toms River, New Jersey 08775, United States
  • CRI Worldwide LLC
    Willingboro, New Jersey 08046, United States
  • Raymond G. Murphy VA Medical Center
    Albuquerque, New Mexico 87108, United States
  • Behavioral Medical Research of Brooklyn
    Brooklyn, New York 11201, United States
  • Comprehensive NeuroScience
    Fresh Meadows, New York 11366, United States
  • North Carolina Psychiatric Research Center
    Raleigh, North Carolina 27603, United States
  • UC Health Clinical Trials Office
    Cincinnati, Ohio 45267, United States
  • Belmont Center for Comprehensive Treatment; Research
    Philadelphia, Pennsylvania 19131, United States
  • Claghorn-Lesem Research Clinic, Inc.
    Bellaire, Texas 77401, United States
  • FutureSearch Clinical Trials, LP
    Dallas, Texas 75231, United States
  • Pillar Clinical Research LLC
    Dallas, Texas 75243, United States
  • Family Psychiatry of the Woodlands P.A.
    The Woodlands, Texas 77381, United States
  • Pacific Institute of Medical Sciences
    Bothell, Washington 98011, United States
  • Eastside Therapeutic Resource
    Kirkland, Washington 98033, United States
  • Centro SERES
    Buenos Aires, 1425, Argentina
  • Fundacion para el Estudio y Tratamiento des las Enfi Mentales
    Buenos Aires, C1425AHQ, Argentina
  • Mulieris
    Caba, C1022AAO, Argentina
  • Facene Fund.Argentina Contra Enferm.Neur.Del Envejecimiento
    Ciudad Autonoma Bs As, 1117, Argentina
  • Instituto Nacional de Psicopatologia
    Ciudad Autonoma Bs As, 1405, Argentina
  • Resolution Psicopharmacology Research Institute
    Ciudad de Mendoza, 5500, Argentina
  • Instituto DAMIC - Fundación Rusculleda
    Cordoba, 5003, Argentina
  • Sanatorio Prof.Leon.S.Morra S.A
    Cordoba, X5009BIN, Argentina
  • Instituto de Neurociencias San Agustín S.A.
    La Plata, 1900, Argentina
  • Centro de Psiquiatria Biologica Professor Julio J. Herrera; Psiquiatria
    Mendoza, 5500, Argentina
  • Centro de Asistencia e Investigación en Neurociencias
    Mendoza, Argentina
  • CIAP - Centro de Investigacion y Asistencia en Psiquiatria
    Rosario, S2000QJI, Argentina
  • Centro de Investigacion Clinica Farmacologica en Psiquiatria
    Santiago del Estero, 4200, Argentina
  • Westmead Hospital; Department of Psychiatry
    Westmead, New South Wales 2145, Australia
  • Monash Medical Centre-Clayton Campus; School of Psychology and Psychiatry
    Clayton, Victoria 3168, Australia
  • Frankston Hospital; Mental Health Service
    Frankston, Victoria 3199, Australia
  • The Alfred Hospital; Monash Alfred Psychiatry Research Centre (MAP-RC)
    Melbourne, Victoria 3004, Australia
  • Centro de Investigaciones y Proyectos en Neurociencias CIPNA
    Barranquilla, Colombia
  • E.S.E. Hospital Mental de Antioquia
    Bello, Colombia
  • Centro de Investigaciones del Sistema Nervioso Limitada - Gr
    Bogota, Colombia
  • Privater
    Kuopio, 70100, Finland
  • Centre Hospitalier Universitaire Caen; Pôle Psychiatrie - Addictologie
    Caen, 14033, France
  • CHU Gabriel Montpied; Service de Psychiatrie
    Clermont-ferrand, 63000, France
  • Centre Hospitalier Specialise du Jura
    Dole, 39100, France
  • Cabinet Médical Ambroise Paré
    Elancourt, 78990, France
  • Hôpital de la Conception; Pôle Psychiatrique Centre
    Marseille, 13005, France
  • CHU Strasbourg Nouvel Hôpital Civil;Service de Psychiatrie I
    Strasbourg, 67091, France
  • Hopital Chalucet; Unite de Psychiatrie
    Toulon, 83000, France
  • Dr. Kenessey Albert Hospital; Psychiatry I.
    Balassagyarmat, 2660, Hungary
  • Fov.Onk.Szt Janos Korh. E-Budai Egyesitett Korhazai; Pszichiatriaci rehabilitacio
    Budapest, 1032, Hungary
  • Semmelweis Egyetem AOK; Pszichiatriai es Pszichoterapias Klinika
    Budapest, 1082, Hungary
  • Fovarosi Onkormanyzat Nyiro Gyula Korhaza; Pszichatria II
    Budapest, 1135, Hungary
  • Fovarosi Onkormanyzat Nyiro Gyula Korhaza; Pszichiatria I.
    Budapest, 1135, Hungary
  • UNO Medical Trials Kft.
    Budapest, 1135, Hungary
  • Petz Aladar Megyei Oktato Korhaz; Pszichiatria I.
    Gyor, 9024, Hungary
  • Békés Megyei Pándy Kálmán Kórház; Onkologiai tanszek
    Gyula, 5703, Hungary
  • Samvedna Hospitals; Samvedana Psychiatry and Sex Therapy Hospital
    Ahmedabad, 380006, India
  • Sneh Clinic
    Ahmedabad, 380008, India
  • Gujarat Institute of Psychological Research (GIPS)
    Ahmedabad, 380015, India
  • Mental Health Care & Research
    Jaipur, 302017, India
  • R. K.Yadav Memorial Mental Health & De-Addiction Hospital
    Jaipur, 302021, India
  • Manav Neuropsychiatric Hospital Pvt. Ltd.
    Kalyan, 421301, India
  • Kasturba Medical College & Hospital
    Mangalore, 575001, India
  • K. S. Hegde Medical Academy
    Mangalore, 575018, India
  • Poona Hospital and Research Centre
    Pune, 411030, India
  • Brij Psychiatry Hospital & Muskaan Research Centre; Maanav Health Foundation
    Vadodara, 390001, India
  • Inje University Busan Paik Hospital
    Busan, 47392, Korea, Republic of
  • Chonnam National University Hospital
    Gwangju, 61469, Korea, Republic of
  • Korea University Ansan Hospital
    Gyeonggi-do, 15355, Korea, Republic of
  • Inha University Hospital
    Incheon, 22332, Korea, Republic of
  • Gil Hospital. Gachon University
    Incheon, 405-760, Korea, Republic of
  • Chonbuk National Uni Hospital
    Jeollabuk-do, 561-712, Korea, Republic of
  • Korea University Anam Hospital
    Seoul, 02841, Korea, Republic of
  • Seoul National University Hospital
    Seoul, 03080, Korea, Republic of
  • The Catholic University of Korea St.Mary's Hospital
    Seoul, 150-713, Korea, Republic of
  • Arete Proycectos y Administracion S.C
    Mexico, 05300, Mexico
  • Centro de Investigacion Medica S.C; Hospital Santa Cecilia de Monterrey S.A. de C.V.
    Monterrey, 64000, Mexico
  • Medikalink
    Monterrey, 64060, Mexico
  • Instituto de informacion e investigacion en salud mental AC
    Monterrey, 64710, Mexico
  • Hospital Lomas de San Luis Internacional
    San Luis Potosi, 72818, Mexico
  • Spitalul Clinic Judetean Arad; Departamentul de Psihiatrie
    Arad, 310022, Romania
  • Spit Univ Urgenta Militar Dr. Carol Davila; Sectia Psihiatrie
    Bucuresti, 010825, Romania
  • Spitalul Clinic de Psihiatrie Prof. Dr. Alexandru Obregia; Clinical III Psihiatrie
    Bucuresti, 041914, Romania
  • Spitalul Clinic de Psihiatrie Prof. Dr. Alexandru Obregia; Comunitara si Reintegrare Psihosociala
    Bucuresti, 041914, Romania
  • Spitalul Clinic de Psihiatrie Prof. Dr. Alexandru Obregia; Sectia Clinica XIII Psihiatrie
    Bucuresti, 041914, Romania
  • Spitalul Clinic Judetean de Urgenta Cluj; Sectia Clinica de Psihiatrie III
    Cluj-Napoca, 400012, Romania
  • Spitalul Universitar de Psihiatrie Socola
    Lasi, 700282, Romania
  • Spitalul Clinic Municipal Dr. Gavril Curteanu; Sectia Clinica Psihiatrie I
    Oradea, 410154, Romania
  • Spitalul de Psihiatrie Dr. Gh. Preda Sibiu;CSM Adulti Sibiu
    Sibiu, 550082, Romania
  • Cabinet Medical S.C. Lorentina 2102 S.R.L.; Psihiatrie
    Targouiste, 130081, Romania
  • Kemerovo Regional Clinical Psychiatric Hospital
    Kemerovo, 650036, Russian Federation
  • GUZ Lipetsk Regional psychoneurological Hospital #1; Dispansary Department
    Lipetsk, 399313, Russian Federation
  • Moscow Region Psychiatric Hospital #5
    Moscow Region, 142601, Russian Federation

Showing the first 100 of 122 sites across 14 countries. Choose a country and city above to see the rest.

08

References and documents

Publications

  • Georgiades A, Davis VG, Atkins AS, Khan A, Walker TW, Loebel A, Haig G, Hilt DC, Dunayevich E, Umbricht D, Sand M, Keefe RSE. Psychometric characteristics of the MATRICS Consensus Cognitive Battery in a large pooled cohort of stable schizophrenia patients. Schizophr Res. 2017 Dec;190:172-179. doi: 10.1016/j.schres.2017.03.040. Epub 2017 Apr 20. PubMed 28433500 ↗
  • Bugarski-Kirola D, Blaettler T, Arango C, Fleischhacker WW, Garibaldi G, Wang A, Dixon M, Bressan RA, Nasrallah H, Lawrie S, Napieralski J, Ochi-Lohmann T, Reid C, Marder SR. Bitopertin in Negative Symptoms of Schizophrenia-Results From the Phase III FlashLyte and DayLyte Studies. Biol Psychiatry. 2017 Jul 1;82(1):8-16. doi: 10.1016/j.biopsych.2016.11.014. Epub 2016 Dec 15. PubMed 28117049 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2010 to primary completion in May 2014, 41 months.

Of 99 industry-sponsored phase 3 interventional studies under Schizophrenia, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 41. This study's 41 months is above that.

Counting every sponsor, half of 113 studies reached it within 32 months; a quarter within 20 and three quarters within 46.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 30, 2010
First posted
Sep 1, 2010
StartActual
Dec 11, 2010
Primary completionActual
May 26, 2014
CompletionActual
May 26, 2014
Results delay requested
Aug 20, 2013
Last update
Jun 26, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 26, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01192867
Lead sponsor
Hoffmann-La Roche
Responsible party
Sponsor
First posted
Sep 1, 2010
Start date
Dec 11, 2010
Primary completion
May 26, 2014
Completion
May 26, 2014
Last update
Jun 26, 2017

Study contacts

Clinical Trials
study director · Hoffmann-La Roche
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Bitopertin

Start the discussion